J&J Launches New TECNIS PureSee™ Intraocular Lens for Presbyopia in India
Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance.
Johnson & Johnson, a global leader in eye health, announced today that its TECNIS PureSee™ purely refractive intraocular lens (IOL) for individuals with presbyopia is now available in India. The TECNIS PureSee™ IOL features a purely refractive design that delivers uninterrupted, high-quality, vision with high best-in-category contrast and low-light performance, comparable to a monofocal IOL.
“Cataract surgery is the most common surgery performed globally, with 28 million procedures each year but only 10-15% of patients are getting advanced optical IOLs specifically designed for addressing issues of astigmatism and presbyopia. We’re proud to launch the TECNIS PureSee™ IOL, giving surgeons and a growing number of patients in India the choice of a premium IOL that combines clarity of vision and reduced visual symptoms.” said Burzin Shahana, Country Manager, Surgical Vision India & South Asia, Johnson & Johnson MedTech.
While choosing any IOL, surgeons and patients have to consider many factors. For example, a lens that offers clear sight at all distances without spectacles, may not be able to remove glares and halos. The purely refractive design of TECNIS PureSee™ lens addresses these issues and therefore improves the overall outcomes for both patients and surgeons.
With its purely refractive design, the TECNIS PureSee™ IOL ensures surgeons’ ease of use in providing high tolerance to refractive error. The TECNIS PureSee™ IOL offers important benefits, including uninterrupted high-quality vision, with excellent distance and intermediate vision, as well as functional near vision for increased spectacle independence. A dysphotopsia profile that is comparable to a monofocal IOL in frequency, bothersome and difficulty levels, which means little to no visual symptoms, such as halos, glares, and starbursts.
By 2050, the number of people aged over 60 years old is expected to more than double to 2.1 billion, and Asia Pacific will account for 65% of the global increase for this age group. Cataracts are the leading cause of treatable blindness in the world. Medical science and technology have advanced today such that a qualified eye surgeon can remove a cataract and replace it with an IOL, and patients typically experience improved eye sight the very same day.